Treatment phase of the Alabama chronic respiratory disease program.
D000407:Alabama; D045930:Anabolic Agents / Q000627:therapeutic use; D001945:Breathing Exercises; D001991:Bronchitis / Q000628:therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D005100:Expectorants / Q000627:therapeutic use*; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D011379:Prognosis; D011656:Pulmonary Emphysema / Q000628:therapy*; D012129:Respiratory Function Tests; D012140:Respiratory Tract Diseases / Q000628:therapy*; D012907:Smoking; D013566:Sympathomimetics / Q000627:therapeutic use; D014970:Xanthines / Q000627:therapeutic use
D045930:Anabolic Agents; D001993:Bronchodilator Agents; D005100:Expectorants; D005938:Glucocorticoids; D013566:Sympathomimetics; D014970:Xanthines